222 related articles for article (PubMed ID: 36321611)
1. Identification of RUNX1 and IFNGR2 as prognostic-related biomarkers correlated with immune infiltration and subtype differentiation of low-grade glioma.
Zhang X; Chu H; Cheng Y; Ren J; Wang W; Liu X; Yan X
Biomol Biomed; 2023 May; 23(3):405-425. PubMed ID: 36321611
[TBL] [Abstract][Full Text] [Related]
2. RUNX1 and REXO2 are associated with the heterogeneity and prognosis of IDH wild type lower grade glioma.
Wang H; Wang X; Xu L; Zhang J; Cao H
Sci Rep; 2021 Jun; 11(1):11836. PubMed ID: 34088969
[TBL] [Abstract][Full Text] [Related]
3. The combined signatures of telomere and immune cell landscape provide a prognostic and therapeutic biomarker in glioma.
Han X; Yan Z; Fan K; Guan X; Hu B; Li X; Ou Y; Cui B; An L; Zhang Y; Gong J
Front Immunol; 2023; 14():1220100. PubMed ID: 37662954
[TBL] [Abstract][Full Text] [Related]
4. DNALI1 is a prognosis-related biomarker and correlates with immune infiltrates in low grade glioma.
Lu Y; Chang P; Bian J; Zhu L
Cancer Biomark; 2023; 38(3):393-407. PubMed ID: 37955080
[TBL] [Abstract][Full Text] [Related]
5. Construction and validation of an immune infiltration-related risk model for predicting prognosis and immunotherapy response in low grade glioma.
Li J; Guo Q; Xing R
BMC Cancer; 2023 Aug; 23(1):727. PubMed ID: 37543576
[TBL] [Abstract][Full Text] [Related]
6. Elevated TYROBP expression predicts poor prognosis and high tumor immune infiltration in patients with low-grade glioma.
Lu J; Peng Y; Huang R; Feng Z; Fan Y; Wang H; Zeng Z; Ji Y; Wang Y; Wang Z
BMC Cancer; 2021 Jun; 21(1):723. PubMed ID: 34162355
[TBL] [Abstract][Full Text] [Related]
7. Positive regulators of T cell functions as predictors of prognosis and microenvironment characteristics of low-grade gliomas.
Li Y; Feng Y; Luo F; Peng G; Li Y
Front Immunol; 2022; 13():1089792. PubMed ID: 36726969
[TBL] [Abstract][Full Text] [Related]
8. Abundant expression of ferroptosis-related SAT1 is related to unfavorable outcome and immune cell infiltration in low-grade glioma.
Mou Y; Zhang L; Liu Z; Song X
BMC Cancer; 2022 Feb; 22(1):215. PubMed ID: 35227235
[TBL] [Abstract][Full Text] [Related]
9. Transforming Growth Factor Beta 2 (TGFB2) mRNA Levels, in Conjunction with Interferon-Gamma Receptor Activation of Interferon Regulatory Factor 5 (IRF5) and Expression of CD276/B7-H3, Are Therapeutically Targetable Negative Prognostic Markers in Low-Grade Gliomas.
Trieu V; Maida AE; Qazi S
Cancers (Basel); 2024 Mar; 16(6):. PubMed ID: 38539537
[TBL] [Abstract][Full Text] [Related]
10. SYT16 is a prognostic biomarker and correlated with immune infiltrates in glioma: A study based on TCGA data.
Chen J; Wang Z; Wang W; Ren S; Xue J; Zhong L; Jiang T; Wei H; Zhang C
Int Immunopharmacol; 2020 Jul; 84():106490. PubMed ID: 32289666
[TBL] [Abstract][Full Text] [Related]
11. PLEKHA4 is a novel prognostic biomarker that reshapes the tumor microenvironment in lower-grade glioma.
Zhi W; Wang Y; Jiang C; Gong Y; Chen Q; Mao X; Deng W; Zhao S
Front Immunol; 2023; 14():1128244. PubMed ID: 37818357
[TBL] [Abstract][Full Text] [Related]
12. Recurrence- and Malignant Progression-Associated Biomarkers in Low-Grade Gliomas and Their Roles in Immunotherapy.
Teng C; Zhu Y; Li Y; Dai L; Pan Z; Wanggou S; Li X
Front Immunol; 2022; 13():899710. PubMed ID: 35677036
[TBL] [Abstract][Full Text] [Related]
13. Next-generation sequencing identifies HOXA6 as a novel oncogenic gene in low grade glioma.
Xiulin J; Wang C; Guo J; Wang C; Pan C; Nie Z
Aging (Albany NY); 2022 Mar; 14(6):2819-2854. PubMed ID: 35349479
[TBL] [Abstract][Full Text] [Related]
14. Hypoxia-Related lncRNA Correlates With Prognosis and Immune Microenvironment in Lower-Grade Glioma.
Xu S; Tang L; Liu Z; Luo C; Cheng Q
Front Immunol; 2021; 12():731048. PubMed ID: 34659218
[TBL] [Abstract][Full Text] [Related]
15. ECM2, a prognostic biomarker for lower grade glioma, serves as a potential novel target for immunotherapy.
Cheng X; Liu Z; Liang W; Zhu Q; Wang C; Wang H; Zhang J; Li P; Gao Y
Int J Biochem Cell Biol; 2023 May; 158():106409. PubMed ID: 36997057
[TBL] [Abstract][Full Text] [Related]
16. Integrated analysis of inflammatory response subtype-related signature to predict clinical outcomes, immune status and drug targets in lower-grade glioma.
Cao Y; Zhu H; Chen Q; Huang H; Xie D; Li X; Jiang X; Ren C; Peng J
Front Pharmacol; 2022; 13():914667. PubMed ID: 36091778
[No Abstract] [Full Text] [Related]
17. IRF7 as an Immune-Related Prognostic Biomarker and Associated with Tumor Microenvironment in Low-Grade Glioma.
Peng S; Wang G; Cheng Z; Guo Z
Int J Gen Med; 2021; 14():4381-4393. PubMed ID: 34413671
[TBL] [Abstract][Full Text] [Related]
18. RUNX1/CD44 axis regulates the proliferation, migration, and immunotherapy of gliomas: A single-cell sequencing analysis.
Zhang H; Cao H; Luo H; Zhang N; Wang Z; Dai Z; Wu W; Liu G; Xie Z; Cheng Q; Cheng Y
Front Immunol; 2023; 14():1086280. PubMed ID: 36776876
[TBL] [Abstract][Full Text] [Related]
19. Profiles of immune-related genes and immune cell infiltration in the tumor microenvironment of diffuse lower-grade gliomas.
Deng X; Lin D; Zhang X; Shen X; Yang Z; Yang L; Lu X; Yu L; Zhang N; Lin J
J Cell Physiol; 2020 Oct; 235(10):7321-7331. PubMed ID: 32162312
[TBL] [Abstract][Full Text] [Related]
20. [IgG Fc binding protein (FCGBP) as a prognostic marker of low-grade glioma and its correlation analysis with immune infiltration].
Liu Q; Zhang J; Zhang F; Zhang W; Gong L
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2023 Aug; 39(8):686-692. PubMed ID: 37515334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
